Vistagen (VTGN) announced that the last patient has completed the randomized, double-blind, placebo-controlled portion of the PALISADE-3 Phase 3 clinical trial evaluating fasedienol for the acute treatment of social anxiety disorder. The open label extension of the study is currently ongoing.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTGN:
- Analysts Predict Up to 550% Rally for These 2 ‘Strong Buy’ Penny Stocks
- VistaGen Therapeutics Appoints Paul R. Edick to Board
- Vistagen’s Phase 3 Trial: A Potential Game-Changer for Anxiety Treatment?
- Vistagen’s Phase 3 Trial of Fasedienol Nasal Spray: A Potential Game-Changer for Anxiety Treatment
- Vistagen’s Promising Phase 2 Trial for Anxiety Treatment: A Market Game Changer?